Regulation of PP2A by sphingolipid metabolism and signaling

Frontiers in Oncology

Volumn 4, Issue , 2015, Pages

  Oaks, Joshua ^a   Ogretmen, Besim ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Ceramide; FTY720; PP2A; Sphingolipids; Tumor suppression

Indexed keywords

CERAMIDE; FINGOLIMOD; PHOSPHOPROTEIN PHOSPHATASE 2A;

CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; GENE EXPRESSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MOLECULAR DOCKING; MULTIPLE SCLEROSIS; POLYCYTHEMIA; REVIEW; SPHINGOLIPID METABOLISM; TUMOR GROWTH;

EID: 85021722110     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00388     Document Type: Review

References (61)

1. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J (2001) 353(Pt 3):417-39. doi:10.1042/0264-6021:3530417
2. Horn V, Thelu J, Garcia A, Albiges-Rizo C, Block MR, Viallet J. Functional interaction of aurora-A and PP2A during mitosis. Mol Biol Cell (2007) 18(4):1233-41. doi:10.1091/mbc. E06-12-1152
3. Low IC, Loh T, Huang Y, Virshup DM, Pervaiz S. Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration of PP2A-B56delta stabilizes its antiapoptotic activity. Blood (2014) 124(14):2223-34. doi:10.1182/blood-2014-03-563296
4. Kremmer E, Ohst K, Kiefer J, Brewis N, Walter G. Separation of PP2A core enzyme and holoenzyme with monoclonal antibodies against the regulatory A subunit: abundant expression of both forms in cells. Mol Cell Biol (1997) 17(3):1692-701.
5. Saydam G, Aydin HH, Sahin F, Selvi N, Oktem G, Terzioglu E, et al. Involvement of protein phosphatase 2A in interferon-alpha-2b-induced apoptosis in K562 human chronic myelogenous leukaemia cells. Leuk Res (2003) 27(8):709-17. doi:10.1016/S0145-2126(02)00347-8
6. Bialojan C, Takai A. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J (1988) 256(1):283-90.
7. Suganuma M, Fujiki H, Suguri H, Yoshizawa S, Hirota M, Nakayasu M, et al. Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. Proc Natl Acad Sci U S A (1988) 85(6):1768-71. doi:10.1073/pnas.85.6.1768
8. Mungre S, Enderle K, Turk B, Porras A, Wu YQ, Mumby MC, et al. Mutations which affect the inhibition of protein phosphatase 2A by simian virus 40 small-t antigen in vitro decrease viral transformation. J Virol (1994) 68(3):1675-81.
9. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell (2005) 8(5):355-68. doi:10.1016/j.ccr.2005.10.015
10. Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, et al. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res (2010) 70(13):5438-47. doi:10.1158/0008-5472.CAN-09-2544
11. Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood (2013) 122(11):1923-34. doi:10.1182/blood-2013-03-492181
12. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med (2013) 5(1):105-21. doi:10.1002/emmm.201201283
13. Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell (2001) 104(1):119-30. doi:10.1016/S0092-8674(01)00196-9
14. Habrukowich C, Han DK, Le A, Rezaul K, Pan W, Ghosh M, et al. Sphingosine interaction with acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) regulates PP2A activity and cyclooxygenase (COX)-2 expression in human endothelial cells. J Biol Chem (2010) 285(35):26825-31. doi:10.1074/jbc. M110. 147058
15. Hoffarth S, ZitzerA, WiewrodtR, Hahnel PS, BeyerV, KreftA, et al. pp32/PHAPI determines the apoptosis response of non-small-cell lung cancer. Cell Death Differ (2008) 15(1):161-70. doi:10.1038/sj.cdd.4402256
16. Hayashi E, Kuramitsu Y, Okada F, Fujimoto M, Zhang X, Kobayashi M, et al. Proteomic profiling for cancer progression: differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics (2005) 5(4):1024-32. doi:10.1002/pmic.200401132
17. Coenen EA, Zwaan CM, Meyer C, Marschalek R, Pieters R, van der Veken LT, et al. KIAA1524: a novel MLL translocation partner in acute myeloid leukemia. Leuk Res (2011) 35(1):133-5. doi:10.1016/j.leukres.2010.08.017
18. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell (2007) 130(1):51-62. doi:10.1016/j.cell.2007.04.044
19. LiN, Abe S, KurataM, Abe-SuzukiS, OnishiI, KirimuraS, et al. Over-expression of cancerous inhibitor of PP2A (CIP2A) in bone marrow cells from patients with a group of high-risk myelodysplastic syndromes. Pathol Oncol Res (2014) 20(2):399-407. doi:10.1007/s12253-013-9709-y
20. Zhai M, Cong L, Han Y, Tu G. CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion. Tumour Biol (2014) 35(2):1123-8. doi:10.1007/s13277-013-1150-z
21. Rantanen T, Kauttu T, Akerla J, Honkanen T, Krogerus L, Salo J, et al. CIP2A expression and prognostic role in patients with esophageal adenocarcinoma. Med Oncol (2013) 30(3):684. doi:10.1007/s12032-013-0684-7
22. Shi F, Ding Y, Ju S, Wu X, Cao S. Expression and prognostic significance of CIP2A in cutaneous malignant melanoma. Biomarkers (2014) 19(1):70-6. doi:10.3109/1354750X.2013.871752
23. XuP, HuangQ, XieF, XuXL, ShaoF. Increased expressionofCIP2Aincholangiocarcinoma and correlation with poor prognosis. Hepatogastroenterology (2013) 60(124):669-72. doi:10.5754/hge11139
24. Wang L, Gu F, Ma N, Zhang L, Bian JM, Cao HY. CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol (2013) 34(4):2309-13. doi:10.1007/s13277-013-0775-2
25. Yi F, Ni W, Liu W, Bai J, Li W. Expression and biological role of CIP2A in human astrocytoma. Mol Med Rep (2013) 7(5):1376-80. doi:10.3892/mmr. 2013.1357
26. Yu G, Liu G, Dong J, Jin Y. Clinical implications of CIP2A protein expression in breast cancer. Med Oncol (2013) 30(2):524. doi:10.1007/s12032-013-0524-9
27. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood (2011) 117(24):6660-8. doi:10.1182/blood-2010-08-304477
28. Wiegering A, Pfann C, Uthe FW, Otto C, Rycak L, Mader U, et al. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PLoS One (2013) 8(10):e75292. doi:10.1371/journal.pone.0075292
29. Carlson SG, Eng E, Kim EG, Perlman EJ, Copeland TD, Ballermann BJ. Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor. J Am Soc Nephrol (1998) 9(10):1873-80.
30. Fornerod M, Boer J, van Baal S, Jaegle M, von Lindern M, Murti KG, et al. Relocation of the carboxyterminal part of CAN from the nuclear envelope to the nucleus as a result of leukemia-specific chromosome rearrangements. Oncogene (1995) 10(9):1739-48.
31. AdachiY, Pavlakis GN, Copeland TD. Identification and characterizationof SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J Biol Chem (1994) 269(3):2258-62.
32. von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene. Mol Cell Biol (1992) 12(8):3346-55.
33. Saito S, Miyaji-Yamaguchi M, Nagata K. Aberrant intracellular localization of SET-CAN fusion protein, associated with a leukemia, disorganizes nuclear export. Int J Cancer (2004) 111(4):501-7. doi:10.1002/ijc.20296
34. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem (1996) 271(19):11059-62. doi:10.1074/jbc.271.19.11059
35. OuelletV, LePage C, Guyot MC, Lussier C, Tonin PN, Provencher DM, et al. SET complex in serous epithelial ovarian cancer. Int J Cancer (2006) 119(9):2119-26. doi:10.1002/ijc.22054
36. Anazawa Y, Nakagawa H, Furihara M, Ashida S, Tamura K, Yoshioka H, et al. PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET. Cancer Res (2005) 65(11):4578-86. doi:10.1158/0008-5472.CAN-04-4564
37. Yu G, Yan T, FengY, Liu X, XiaY, Luo H, et al. Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease. Neurobiol Aging (2013) 34(7):1748-58. doi:10.1016/j.neurobiolaging.2012.12.025
38. Irie A, Harada K, Araki N, Nishimura Y. Phosphorylation of SET protein at Ser171 by protein kinase D2 diminishes its inhibitory effect on protein phosphatase 2A. PLoS One (2012) 7(12):e51242. doi:10.1371/journal.pone. 0051242
39. Vasudevan NT, Mohan ML, Gupta MK, Hussain AK, Prasad SV. Inhibition of protein phosphatase2AactivitybyPI3Kgammaregulates beta-adrenergic receptor function. Mol Cell (2011) 41(6):636-48. doi:10.1016/j.molcel.2011.02.025
40. Furuya H, Shimizu Y, Kawamori T. Sphingolipids in cancer. Cancer Metastasis Re v (2011) 30(3-4):567-76. doi:10.1007/s10555-011-9304-1
41. Kim JY, Lee KS, Seol JE, Yu K, Chakravarti D, Seo SB. Inhibition of p53 acetylation by INHAT subunit SET/TAF-Ibeta represses p53 activity. Nucleic Acids Res (2012) 40(1):75-87. doi:10.1093/nar/gkr614
42. KimJY, Kim KB, Son HJ, ChaeYC, OhST, KimDW, et al. H3K27 methylationand H3S28 phosphorylation-dependent transcriptional regulation by INHAT subunit SET/TAF-Ibeta. FEBS Lett (2012) 586(19):3159-65. doi:10.1016/j.febslet. 2012.06.026
43. Saito S, Miyaji-Yamaguchi M, Shimoyama T, Nagata K. Functional domains of template-activating factor-I as a protein phosphatase 2A inhibitor. Biochem Biophys Res Commun (1999) 259(2):471-5. doi:10.1006/bbrc.1999.0790
44. Karetsou Z, Emmanouilidou A, Sanidas I, Liokatis S, Nikolakaki E, Politou AS, et al. Identification of distinct SET/TAF-Ibeta domains required for core histone binding and quantitative characterisation of the interaction. BMC Biochem (2009) 10:10. doi:10.1186/1471-2091-10-10
45. Beresford PJ, Kam CM, Powers JC, Lieberman J. Recombinant human granzyme A binds to two putative HLA-associated proteins and cleaves one of them. Proc Natl Acad Sci U S A (1997) 94(17):9285-90. doi:10.1073/pnas.94.17.9285
46. Arnaud L, Chen S, Liu F, Li B, Khatoon S, Grundke-Iqbal I, et al. Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET. FEBS Lett (2011) 585(17):2653-9. doi:10.1016/j.febslet. 2011.07.020
47. Miyaji-Yamaguchi M, Okuwaki M, Nagata K. Coiled-coil structuremediated dimerization of template activating factor-I is critical for its chromatin remodeling activity. J Mol Biol (1999) 290(2):547-57. doi:10.1006/jmbi. 1999.2898
48. Christensen DJ, ChenY, Oddo J, Matta KM, Neil J, Davis ED, et al. SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood (2011) 118(15):4150-8. doi:10.1182/blood-2011-04-351072
49. Dobrowsky RT, Kamibayashi C, Mumby MC, Hannun YA. Ceramide activates heterotrimeric protein phosphatase 2A. J Biol Chem (1993) 268(21):15523-30.
50. Kowluru A, Metz SA. Ceramide-activated protein phosphatase-2A activity in insulin-secreting cells. FEBS Lett (1997) 418(1-2):179-82. doi:10.1016/S0014-5793(97)01379-3
51. Chalfant CE, Kishikawa K, Mumby MC, Kamibayashi C, Bielawska A, Hannun YA. Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J Biol Chem (1999) 274(29):20313-7. doi:10.1074/jbc.274.29.20313
52. Perry DM, Kitatani K, Roddy P, El-Osta M, Hannun YA. Identification and characterization of protein phosphatase 2C activationby ceramide. J Lipid Res (2012) 53(8):1513-21. doi:10.1194/jlr. M025395
53. Nagahara Y, Matsuoka Y, Saito K, Ikekita M, Higuchi S, Shinomiya T. Coordinate involvement of cell cycle arrest and apoptosis strengthen the effect of FTY720. Jpn J Cancer Res (2001) 92(6):680-7. doi:10.1111/j.1349-7006.2001. tb01148.x
54. Kovarik JM, Schmouder R, Barilla D, Wang Y, Kraus G. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol (2004) 57(5):586-91. doi:10.1111/j.1365-2125.2003. 02065.x
55. Chalfant CE, Szulc Z, Roddy P, BielawskaA, Hannun YA. The structural requirements for ceramide activation of serine-threonine protein phosphatases. J Lipid Res (2004) 45(3):496-506. doi:10.1194/jlr. M300347-JLR200
56. Mukhopadhyay A, Saddoughi SA, Song P, Sultan I, Ponnusamy S, Senkal CE, et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipidprotein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J (2009) 23(3):751-63. doi:10.1096/fj.08-120550
57. Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell (2013) 23(1):107-20. doi:10.1016/j.ccr.2012.11.013
58. Liu Q, Zhao X, Frissora F, MaY, Santhanam R, Jarjoura D, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood (2008) 111(1):275-84. doi:10.1182/blood-2006-10-053884
59. Mukhopadhyay A, Tabanor K, Chaguturu R, Aldrich JV. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment. Cancer Biol Ther (2013) 14(10):962-72. doi:10.4161/cbt.25943
60. Obeid LM, Linardic CM, Karolak LA, Hannun YA. Programmed cell death induced by ceramide. Science (1993) 259(5102):1769-71. doi:10.1126/science. 8456305
61. Chen L, Luo LF, Lu J, Li L, Liu YF, Wang J, et al. FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels. PLoS One (2014) 9(7):e103033. doi:10.1371/journal.pone.0103033